The effect ofspp. on the prevention or treatment of COVID-19 and other respiratory tract infections in humans: A rapid review.
Adv Integr Med. 2020 Aug 1. Epub 2020 Aug 1. PMID: 32837894
Brief overview: Current evidence suggests thatsupplementation may decrease the duration and severity of acute respiratory tract infections; however, no studies usingin the prevention or treatment of conditions similar to COVID-19 have been identified. Few adverse events were reported, suggesting that this herbal therapy is reasonably safe. Becausecan increase immune function, there is a concern that it could worsen over-activation of the immune system in cytokine storm; however, clinical trials show thatdecreases levels of immune molecules involved in cytokine storm.
Verdict: supplementation may assist with the symptoms of acute respiratory infections (ARI) and the common cold, particularly when administered at the first sign of infection; however, no studies usingin the prevention or treatment of conditions similar to COVID-19 have been identified. Previous studies have reported thatmay decrease the severity and/or duration of ARI when taken at the onset of symptoms. The studies reporting benefit usedor a combination ofandcontaining standardized amounts of active constituents.Few adverse events from the use ofwere reported, suggesting that this herbal therapy is reasonably safe. No human trials could be located reporting evidence of cytokine storm whenwas used for up to 4 months.When assessing all human trials which reported changes in cytokine levels in response tosupplementation, the results were largely consistent with a decrease in the pro-inflammatory cytokines that play a role in the progression of cytokine storm and Acute Respiratory Distress Syndrome (ARDS), factors that play a significant role in the death of COVID-19 patients. While there is currently no research on the therapeutic effects ofin the management of cytokine storm, this evidence suggests that further research is warranted.